The phase I trials of Elimusertib and Berzosertib provided the clinical evidence of durable single-agent antitumor activity of an ATR inhibitor in patients with advanced cancers with ATM aberrations (ATM protein expression loss and/or ATM deleterious mutation), supporting a synthetically lethal interaction between ATM deficiency and ATR inhibition [66,67]. This evidence concerns the gene ATM and cancer.